WO1996011266A3 - Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci - Google Patents

Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci Download PDF

Info

Publication number
WO1996011266A3
WO1996011266A3 PCT/US1995/012770 US9512770W WO9611266A3 WO 1996011266 A3 WO1996011266 A3 WO 1996011266A3 US 9512770 W US9512770 W US 9512770W WO 9611266 A3 WO9611266 A3 WO 9611266A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
cell proliferation
smooth muscle
muscle cell
inhibiting smooth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/012770
Other languages
English (en)
Other versions
WO1996011266A2 (fr
Inventor
Teresa L Burgess
Catherine L Farrell
Eric F Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to AU38895/95A priority Critical patent/AU3889595A/en
Publication of WO1996011266A2 publication Critical patent/WO1996011266A2/fr
Publication of WO1996011266A3 publication Critical patent/WO1996011266A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des oligonucléotides multi-G capables d'inhiber la prolifération de cellules musculaires lisses. Les oligonucléotides multi-G de l'invention peuvent être utilisés en tant que composés thérapeutiques d'acides nucléiques afin d'inhiber la prolifération de cellules musculaires lisses dans des artères ex vivo, et plus particulièrement contre la resténose. L'invention concerne également des compositions pharmaceutiques contenant les oligonucléotides multi-G. En outre, l'invention concerne un procédé de triage d'oligonucléotides en fonction de leur aptitude à inhiber la prolifération de cellules musculaires lisses ex vivo.
PCT/US1995/012770 1994-10-05 1995-10-03 Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci Ceased WO1996011266A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38895/95A AU3889595A (en) 1994-10-05 1995-10-03 Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31845894A 1994-10-05 1994-10-05
US08/318,458 1994-10-05

Publications (2)

Publication Number Publication Date
WO1996011266A2 WO1996011266A2 (fr) 1996-04-18
WO1996011266A3 true WO1996011266A3 (fr) 1996-12-12

Family

ID=23238272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012770 Ceased WO1996011266A2 (fr) 1994-10-05 1995-10-03 Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci

Country Status (2)

Country Link
AU (1) AU3889595A (fr)
WO (1) WO1996011266A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840669D1 (de) 1997-04-10 2009-04-30 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
EP1222266B1 (fr) 1999-09-29 2006-03-29 Diagnocure Inc. L'arnm du pca3 dans les tissus benins et malins de la prostate
EP1592809B1 (fr) 2003-02-07 2013-04-10 Diagnocure Inc. Procede de detection de cancer de la prostate dans un echantillon
CA2491067A1 (fr) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Rapport entre arnm dans les sediments urinaires ou l'urine en tant que marqueur pronostique du cancer de la prostate
WO2009073809A2 (fr) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Conjugués glucidiques utilisés en tant qu'agents d'administration pour des oligonucléotides
WO2009086558A1 (fr) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Compositions et procédés améliorés pour la délivrance d'acides nucléiques
CA2721333C (fr) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Nouvelles formulations lipidiques pour l'administration d'acides nucleiques
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
WO2011000107A1 (fr) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Formulations lipidiques inédites permettant l'administration d'agents thérapeutiques en direction de tumeurs solides
EP3296398A1 (fr) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Nanoparticules pour l'administration d'acide nucléique
EP3494963A1 (fr) 2009-12-18 2019-06-12 The University of British Columbia Procédés et compositions d'administration d'acides nucléiques
WO2012016184A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour la délivrance d'agents actifs
WO2012016188A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour l'administration d'agents actifs
CA2824526C (fr) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Lipides pegyles et leur utilisation pour une administration de medicament
EP3456317B1 (fr) 2011-09-27 2025-09-24 Alnylam Pharmaceuticals, Inc. Lipides di-aliphatiques pegylés substitués
EP2817287B1 (fr) 2012-02-24 2018-10-03 Arbutus Biopharma Corporation Lipides cationiques trialkylés et leurs procédés d'utilisation
WO2015006740A2 (fr) 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Conjugués ligands d'oligonucléotides et procédé pour leur préparation
EP4058032A4 (fr) 2019-12-19 2024-01-10 Entrada Therapeutics, Inc. Compositions pour administrer des composés antisens
EP4121018A4 (fr) 2020-03-17 2024-07-03 Genevant Sciences Gmbh Lipides cationiques pour l'administration de nanoparticules lipidiques d'agents thérapeutiques à des cellules stellaires hépatiques
AU2021403156A1 (en) 2020-12-18 2023-07-13 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles
EP4314016A1 (fr) 2021-03-31 2024-02-07 Entrada Therapeutics, Inc. Peptides de pénétration cellulaire cyclique
EP4337263A1 (fr) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions et méthodes de modulation de l'activité du facteur 5 de régulation de l'interféron (irf-5)
AU2022271873A1 (en) 2021-05-10 2024-01-04 Entrada Therapeutics, Inc. Compositions and methods for intracellular therapeutics
AU2022298774A1 (en) 2021-06-23 2023-12-14 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
US12465647B2 (en) 2021-08-05 2025-11-11 Sanegene Bio Usa Inc. 1′-alkyl modified ribose derivatives and methods of use
EP4405368A1 (fr) 2021-09-22 2024-07-31 Sanegene Bio USA Inc. Dérivés de ribose modifiés par 2'-alkyle ou 3'-alkyle destinés à être utilisés dans l'administration in vivo d'oligonucléotides
EP4413015A1 (fr) 2021-10-05 2024-08-14 Sanegene Bio USA Inc. Dérivés de cyclopentane polyhydroxylés et procédés d'utilisation
CN118900701A (zh) 2022-01-31 2024-11-05 盖纳万科学有限公司 聚(烷基噁唑啉)-脂质缀合物及含有聚(烷基噁唑啉)-脂质缀合物的脂质颗粒
KR20240146674A (ko) 2022-01-31 2024-10-08 제네반트 사이언시즈 게엠베하 지질 나노입자를 위한 이온화 가능한 양이온성 지질
US20230346819A1 (en) 2022-02-22 2023-11-02 Sanegene Bio Usa Inc. 5'-modified carbocyclic ribonucleotide derivatives and methods of use
EP4555088A1 (fr) 2022-07-11 2025-05-21 Sanegene Bio USA Inc. Dérivés du ribose modifié en 2' optimisés et procédés d'utilisation
MX2025013094A (es) 2023-05-03 2026-02-03 Sanegene Bio Usa Inc Conjugados basados en lipidos para la administracion sistemica en el sistema nervioso central, el sistema nervioso periferico y ocular
US20250064939A1 (en) 2023-07-24 2025-02-27 Sanegene Bio Usa Inc. Lipid-based enhancement agent for rna delivery and therapy
WO2025052278A1 (fr) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Lipides cationiques à base de pyrrolidine pour administration de nanoparticules lipidiques d'agents thérapeutiques à des cellules stellaires hépatiques
WO2025133951A1 (fr) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Lipides ionisables appropriés pour des nanoparticules lipidiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (fr) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Therapie localisee utilisant des oligonucleotides
WO1994008053A1 (fr) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides possedant une sequence noyau g4 conservee

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (fr) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Therapie localisee utilisant des oligonucleotides
WO1994008053A1 (fr) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides possedant une sequence noyau g4 conservee

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURGESS, T. ET AL.: "The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, no. 9, 25 April 1995 (1995-04-25), WASHINGTON US, pages 4051 - 4055, XP002015216 *
ECKER, D. ET AL.: "Rational screening of oligonucleotide combinatorial libraries for drug discovery", NUCLEIC ACIDS RESEARCH, vol. 21, no. 8, 25 April 1993 (1993-04-25), OXFORD GB, pages 1853 - 1856, XP002015215 *
FARRELL, C. ET AL.: "The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 5, 1995, US, pages 175 - 183, XP002015217 *
YASWEN, P. ET AL.: "Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 3, no. 1, 1993, US, pages 67 - 77, XP002015214 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids

Also Published As

Publication number Publication date
AU3889595A (en) 1996-05-02
WO1996011266A2 (fr) 1996-04-18

Similar Documents

Publication Publication Date Title
WO1996011266A3 (fr) Procede d'inhibition de la proliferation des cellules musculaires lisses et oligonucleotides utilises dans celui-ci
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
HUP0200804A3 (en) The use of pharmaceutical compositions containing 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
BR9808109A (pt) Inibidor terapêutico de células vasculares da musculatura lisa
HUP0002037A3 (en) Hydroximic acid derivatives, use of them for producing pharmaceutical compositions suitable for inhibiting matrix metalloproteinas and pharmaceutical compositions containing the compounds
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
HUP0301101A3 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
HUP0102477A3 (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases and pharmaceutical compositions containing the compounds
HU9502587D0 (en) Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
CA2268394A1 (fr) Nouveaux derives de pyrazol heterocyclylmethyle-substitues
EP1420009A3 (fr) Nouveaux dérivés d'acides amines présentant une meilleure activité contre la résistance à plusieurs médicaments
NZ333373A (en) Use of amino acid derivatives for preparing compositions with improved multi-drug resistance activity
UA74325C2 (uk) ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ р38, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇХ МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ ЗА ЇХ ДОПОМОГОЮ
HUP0203376A3 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them and their use
IL114586A (en) Droloxifene for use in the treatment of cardiovascular diseases and pharmaceutical compositions comprising same
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
ZA9210080B (en) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them.
HUP0000678A3 (en) Aminobenzophenones as inhibitors of interleukin and tnf, process for their preparation and pharmaceutical compositions containing the same
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
HUP0200881A2 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
GB9804025D0 (en) Orthomolecular medical use of L-citrulline for vasprotection,relaxative smooth muscle tone and cell protection
HU9503609D0 (en) Arylacetamides, process for their preparation, compositions containing them and their use as fungicides
HUP9900071A3 (en) Tribenzimidazoles useful as topoisomerase i inhibitors, pharmaceutical compositions containing them and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase